*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** As a reminder, this is my personal guide. You can alter it in accordance with your risk tolerance. >3 Standard deviations – No position 2-3 […]
March 10 Biotech Update
The sector has been interesting. Given the past 18 months, it feels easy to be bearish on every pullback consolidation but I am incrementally more positive. It is starting to feel more like a pause at an important level of resistance as opposed to the start of a large retracement. Obviously we likely need some […]
February 3 Biotech Update
I was correct in my prediction that I would need to take care of a sick child (and still need to do so today but have some more time). It has been an interesting week but pretty much expected. I will circle around to what I saw as the most interesting and important events. 1. […]
June 29 Biotech Update
Brexit fears are turning into Brexit relief as I talked about Monday but there is still awhile to go before the damage to the market and sector are fixed and we probably need to go over the pre-Brexit levels before getting more comfortable. In any case, there is some interesting biotech news to talk about. […]
April 4 Biotech Update
It is a pretty quiet start to the week (again) but a little less so than previous weeks. At least we have a GILD deal to think about, although not the one everyone was expecting (hoping for). While I certainly would like to see the sector rocket higher, there is something to be said for […]
September 29 Biotech Update
I want to get out a quick note this morning as I am not sure I will have time for my usual Wednesday note and there has been some interesting news. The biggest issue remains the macro and the selloff in the sector. This is beyond weak hands and this is the liquidation of large […]
September 16 Biotech Update
The market has done well recently but it is all meaningless for the most part until we get the Fed decision. To be honest, I do not know whether to root for a hike or no-hike. I can come up with what I think are reasonable cases for why the market would rally on either […]
August 31 Biotech Update
Looks like a slightly lower start to the week. Macro still obviously matters but the size of the moves seems to be decreasing. I find it interesting that the weakness comes after Fisher had a relatively hawkish Fed talk at Jackson Hole, where he noted that the Fed could raise rates before they saw inflation. […]
August 28 Biotech Update
I was busy for a day and the market does great but I come back and we have a gap lower. Sorry. In all seriousness, however, the snap back rally needs to pause but given the sell-off, I think we need to see the market shake off the gap lower and end higher today. We […]
August 19 Biotech Update
Not much has changed sector wide since I last wrote but we did have a trade play out, although not quite the way I expected. I want to talk about it today both because there have been some questions around it but also because it goes to the larger theme I think is at work […]
August 7 Biotech Update
I am not able to write for a couple of days and the market goes to crap, I figured you all would be able to keep down the fort better than that. As much as it seems like a beating (it is) I do not think we are seeing the bubble burst (of course, I […]
July 30 Biotech Update
The sector is pretty weak, which is a continuation of the past couple of days. It is not immediately clear to me the reason for the weakness as earnings have been almost universally good (notable exception being BIIB). Given the lack of news, I will spend today brainstorming some ideas for the weakness as well […]
July 27 Biotech Update
The market looks bad and it is bringing down the sector although I think BIIB has done a pretty good job at reversing some bullish biotech sentiment. That being said the sector might be outperforming the broader market a little as there was a nice big deal announced this morning. When all is said and […]
July 24 Biotech Update
Unlike earlier this week where bad news was shrugged off, it looks like we are going to see selling on the bad news. This pullback should eventually generate nice bargains if it picks up steam but it might not be an immediate buy the dip as earning have been relatively mixed, so money may be […]
June 15 Biotech Update
It is a macro world and we are just living in it. Sunday night we should have known this was going to be a bad start to the week with the two themes being Greece and the biotech bubble. Both themes are pretty trite but they are both negative headline risks. Outside of the headline […]
June 10 Biotech Update
This is sort of a different start to the day with the market off to a good start but biotechs the obvious laggard. The sector had been one of the relative bright spots but now that the market is recovering, they are lagging. This seems more news related (discussed below) and we need to see […]
June 3 Biotech Update
Yesterday was not a great day for the sector with reports of a large sell program in large caps and from what I saw that makes sense. None of the large caps really seemed to rally and every move higher was met with selling. SMID did a little better but we still likely need the […]
March 25 Biotech Update
A rough start to morning for the sector with a biotech bubble article in the WSJ not helping. There was nothing new but the headline is the headline (it also had some odd numbers like CELG P/E over 50, which is much higher than the numbers I usually see when calculating CELG P/E). Of course, […]
March 18 Biotech Update
Some early weakness but I also suspect today is going to be fairly volatile with the Fed weighing in later this afternoon. So I am really not going to read anything into the price action this morning and even less into the price action in the sector after the announcement. Given how close people think […]
March 17 Biotech Update
The market is weak but the biotech sector is showing good strength. The large caps seem to be holding up their end of the bargain, which bodes well for this move. I do wonder when the new leg down in oil prices hits the broader market. It seems to be handling it well but if […]
